• Sales growth of 6.8%, driven by the solid performance of Theranostics at +13%
• 2021 net income of -€767K, impacted by non-recurring charges of €496K
• H2 2021 net income excluding non-recurring charges close to break-even at -€33K and demonstrating continuous improvement in operations
• Solid cash position at €7.1 million
Theradiag is organizing a videoconference today, at 6:00 p.m. (CET).
To participate, please register on the following link:
https://us02web.zoom.us/webinar/register/WN_M39RZ67nSxCHLhie7hlJHg